Summary
This prediction ended on 22.09.17 with a price of €16.78. The SELL prediction by klostergang closed unchanged from the start price. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Versartis | - | - | - | - |
iShares Core DAX® | -0.531% | 3.824% | 15.862% | 16.424% |
iShares Nasdaq 100 | 2.338% | 3.067% | 21.901% | 35.414% |
iShares Nikkei 225® | 1.332% | 5.933% | 12.099% | -0.322% |
iShares S&P 500 | 1.181% | 3.042% | 22.103% | 38.834% |
Comments by klostergang for this prediction
In the thread Versartis diskutieren
Versartis' lead candidate VRS-317 flunks late-stage study
Thinly traded small cap Versartis (NASDAQ:VSAR) is set for a tumble after reporting negative results in a Phase 3 clinical trial, VELOCITY, assessing lead candidate somavaratan (VRS-317) for the treatment of pediatric growth hormone deficiency.
(Zielkurs erreicht)